Share Email Print

Proceedings Paper

Prostatron 30-minute update: where do we stand
Author(s): James C. Ulchaker; Justin Albani
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

The urologic management of benign prostatic hyperplasia (BPH) beyond pharmaco-therapy has changed dramatically over the last decade. Open prostatectomy and transurethral resection of the prostate (TURP) have been the mainstays of surgical intervention for BPH. These procedures were initially reserved for patients with obstructive uropathy, prostatic bleeding, or bladder calculi. With improved techniques and lower morbidity, TURP is currently the "gold standard" of treatment for patients with BPH and troubling lower urinary tract symptoms (LUTS), and patients are being treated prior to the development of these adverse sequelae. Nevertheless, TURP is still major surgery, requiring either a spinal or general anesthetic and an inpatient hospital stay. Furthermore, TURP is not uniformly successful. Up to 30% of patients report dissatisfaction from the procedure. Complications have been well described and include bleeding, bladder-neck contracture, erectile dysfunction retrograde ejaculation, urinary incontinence, and fluid/electrolyte imbalance (post-TUR syndrome). The mortality rate for TURP is approx. 2 - 10/1000 cases. Over the past decade, the number of TURPs being performed has been decreasing as minimally invasive therapies, including alpha-adrenergic blockers, are being used as "first-line" management with increasing frequency and success. In addition, urologists no longer just treat ill patients in urinary retention. The treatment paradigm has evolved to include patients with persistently troubling symptoms of bladder-outlet obstruction, prior to the development of such adverse sequelae. Furthermore, patients see the care of a urologist on an elective basis, and they frequently wish to avoid surgery. As described in prior chapters, advancements in our understanding of the pathophysiology of BPH have led toimprovements in its medical management and have delayed or precluded surgery in many patients. However, when pharmacotherapy fails, further treatment options need to be discussed. Minimally invasive therapies for BPH have evolved out of this need to "bridge the gap" between medical and surgical managment. This chapter describes the current modalities of minimally invasive treatment for benign prostatic obstruction caused by prostatic lobar hyperplasia, and their respective roles in our office practice.

Paper Details

Date Published: 12 September 2003
PDF: 5 pages
Proc. SPIE 4949, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XIII, (12 September 2003); doi: 10.1117/12.476384
Show Author Affiliations
James C. Ulchaker, Cleveland Clinic Foundation (United States)
Justin Albani, Cleveland Clinic Foundation (United States)

Published in SPIE Proceedings Vol. 4949:
Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems XIII
Eugene A. Trowers; Timothy A. Woodward; Werner T.W. de Riese; Lawrence S. Bass; Nikiforos Kollias; Udayan K. Shah; Brian Jet-Fei Wong; Reza S. Malek; David S. Robinson; Hans-Dieter Reidenbach; Keith D. Paulsen; Kenton W. Gregory; Lawrence S. Bass; Abraham Katzir, Editor(s)

© SPIE. Terms of Use
Back to Top